Human
papilloma
virus
(
HPV
)
-associated
head
neck
carcinoma
quite
heterogeneous
tumors
arise
oral
cavity
,
oropharynx
,
hypopharynx
larynx
.

HPV
recently
recognized
emerging
risk
factor
oropharyngeal
squamous
cell
carcinoma
(
OSCC
)
.

HPV
(
+
)
tumors
represent
5-20
%
head
neck
squamous-cell
carcinomas
(
HNSCCs
)
40-90
%
arising
oropharynx
,
widely
variable
rates
depending
geographic
area
,
population
,
relative
prevalence
environment-related
SCC
detection
assay
.

Different
carcinogenic
mechanisms
likely
implicated
cervical
oropharyngeal
carcinogenesis
.

The
certain
carcinogenic
genotype
head
neck
region
common
high-risk
HPV
genotype
,
HPV-16
,
frequently
detected
OSCC
.

A
combination
p16INK4A
expression
molecular
detection
HPV
DNA
gold
standard
viral
identification
tissue
exfoliated
cell
samples
.

Differences
biology
HPV
(
+
)
HPV
(
-
)
OSCC
may
implications
management
patients
.

New
immunotherapy
drugs
based
release
co-inhibitory
receptors
,
cytotoxic
T-lymphocyte-associated
antigen
4
(
CTLA-4
)
programmed-death
1
(
PD-1
)
currently
emerged
.

The
goal
therapeutic
cancer
vaccination
inculcation
persistent
,
tumor
antigen-specific
T
cell
response
kills
tumor
cells
.

The
efficacy
current
HPV
vaccines
,
Cervarix
Gardasil
,
preventing
HPV-related
HNSCC
present
unknown
.

Treatment
de-escalation
recommended
current
management
HPV-induced
HNSCCs
.

